Cyclophosphamide versus bolus in Wegener’s granulomatosis and other ANCA-related vasculitides : Advantages and disadvantages

[Article in German]
Reinhold-Keller E, Warnatz K.
Rheumaklinik Bad Bramstedt & Internistisch-rheumatologische Gemeinschaftspraxis Hamburg, Oskar-Alexander-Str. 26, 24576, Bad Bramstedt, Deutschland,

Cyclophosphamide remains the therapy of choice in severe ANCA positive vasculitis. In order to avoid the considerable side effects of high cumulative doses sometimes manifesting themselves years later, induction therapy with a low cyclophosphamide dose and an early switch to cyclophosphamide-free maintenance regimens should be aimed for. This can be achieved by an induction therapy of 3–6 months of intravenous pulse therapy (pCYC) or oral therapy (oCYC). The metaanalysis of therapeutic trials in ANCA vasculitis demonstrates a slightly higher induction rate of remission, but an increased relapse rate of pCYC compared to oCYC. The incidence of adverse events seems to be higher in oCYC compared to pCYC. The results of the first controlled prospective multicenter trial (CYCLOPS) directly comparing pCYC and oCYC treatment of ANCA-positive vasculitis are eagerly awaited. It will be important to extend the follow-up over several years in order to reach a valid estimate of the incidence of secondary malignancies due to CYC therapy.

PMID: 19093127 [PubMed – as supplied by publisher]

Abstract was found here.

My notes: I have used both oral and pulse cychlophosphamide. Because of my problems with inflammation, I had one year of pulse. A year later I had 6 months of oral. Thankfully, I am now on imuran to keep my disease under control. I am very interested in this type of research. Knowing how the medications affect us long term will help us to survive longer with healthier lives.


About Cyn Bagley

My life is a mixture of travel, jobs, and disease. You can find some of my novels on under the name Cyn Bagley.
This entry was posted in research, Wegener's Granulomatosis. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s